CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
The Food and Drug Administration on Tuesday approved a new, extended-release form of the HIV nucleoside reverse transcriptase inhibitor Zerit (d4T), which will be marketed as Zerit XR by drugmaker Bristol-Myers Squibb. The new formulation can be taken just once a day. Data from clinical trials of the medication show that it is as effective as the standard twice-daily dosing of d4T and that reducing the pill burden may help people with HIV better stick to their anti-HIV drug regimens.
From our Sponsors
Most Popular
Watch Now: Pride Today
Latest Stories
Ellen DeGeneres shows unexpected support for Rosie O'Donnell in Trump feud
July 14 2025 12:19 PM
Florida Republican official suspended for social posts mocking Pulse murder victims
July 14 2025 11:41 AM
How drag artists can protect themselves from the far-right attacks
July 14 2025 6:00 AM
Donald Trump threatens to revoke Rosie O'Donnell's citizenship — but he can't
July 12 2025 6:04 PM
Ahead of deadly Texas floods, so many warnings from climate scientists were missed
July 12 2025 7:00 AM
Louisiana Medicaid quietly stops reimbursing patients for gender-affirming care
July 11 2025 3:35 PM